<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33739899</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>773</EndPage><MedlinePgn>763-773</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2021.1906755</ELocationID><Abstract><AbstractText>Coxsackievirus A6 (CV-A6) has been emerging as a major pathogen of hand, foot and mouth disease (HFMD). Study on the pathogenesis of CV-A6 infection and development of vaccines is hindered by a lack of appropriate animal models. Here, we report an actively immunized-challenged mouse model to evaluate the efficacy of a Vero-cell-based, inactivated CV-A6 vaccine candidate. The neonatal Kunming mice were inoculated with a purified, formaldehyde-inactivated CV-A6 vaccine on days 3 and 9, followed by challenging on day 14 with a naturally selected virulent strain at a lethal dose. Within 14 days postchallenge, all mice in the immunized groups survived, while 100% of the Alum-only inoculated mice died. Neutralizing antibodies (NtAbs) were detected in the serum of immunized suckling mice, and the NtAb levels correlated with the survival rate of the challenged mice. The virus loads in organs were reduced, and pathological changes and viral protein expression were weak in the immunized mice compared with those in Alum-only inoculated control mice. Elevated levels of interleukin-4, 6, interferon &#x3b3; and tumour necrosis factor &#x3b1; were also observed in Alum-only control mice compared with immunized mice. Importantly, the virulent CV-A6 challenge strain was selected quickly and conveniently from a RD cell virus stock characterized with the natural multi-genotypes. The virulent determinants were mapped to V124M and I242&#x2005;V at VP1. Together, our results indicated that this actively immunized mouse model is invaluable for future studies to develop multivalent vaccines containing the major component of CV-A6 against HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Sha-Sha</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Zhen-Ni</ForeName><Initials>ZN</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Wei-Ping</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yan-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Sheng-Li</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ze-Jun</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Shuo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8378-3770</Identifier><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CV-A6 vaccine</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">active immunization-challenge</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>17</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33739899</ArticleId><ArticleId IdType="pmc">PMC8079124</ArticleId><ArticleId IdType="doi">10.1080/22221751.2021.1906755</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Esposito S, Principi N.. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Zhang XA, Wo Y, et al. . Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009&#x2013;2011. PLoS One. 2012;7(12):e52073. 10.1371/journal.pone.0052073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC.. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot and mouth disease. Expert Rev Vaccines. 2018;17(9):819&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian LL, Wang YP, Yao X, et al. . Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther. 2015;13(9):1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">26112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterback R, Vuorinen T, Linna M, et al. . Coxsackievirus A6 and hand, foot and mouth disease, Finland. Emerg Infect Dis. 2009;15(9):1485&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819858</ArticleId><ArticleId IdType="pubmed">19788821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca MC, Sarmiento L, Resik S, et al. . Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011&#x2013;2013. Arch Virol. 2014;159(9):2451&#x2013;2455.</Citation><ArticleIdList><ArticleId IdType="pubmed">24719197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisterna DM, Lema CL, Martinez LM, et al. . Atypical hand, foot and mouth disease caused by coxsackievirus A6 in Argentina in 2015. Rev Argent Microbiol. 2019;51(2):140&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">30269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CTK, Jiang L, Ma S, et al. . Basic reproduction number of coxsackievirus type A6 and A16 and enterovirus 71: estimates from outbreaks of hand, foot and mouth disease in Singapore, a tropical city-state. Epidemiol Infect. 2016;144(5):1028&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374168</ArticleId></ArticleIdList></Reference><Reference><Citation>He SZ, Chen MY, Wu WH, et al. . An emerging and expanding clade accounts for the persistent outbreak of coxsackievirus A6-associated hand, foot and mouth disease in China since 2013. Virology. 2018;518:328&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">29587191</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng XD, Tong YQ, Wei ZN, et al. . Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China. Sci Rep. 2020;10(1):20909. 10.1038/s41598-020-77768-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77768-7</ArticleId><ArticleId IdType="pmc">PMC7708472</ArticleId><ArticleId IdType="pubmed">33262488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmis BD, Downing C, Tyring S.. Hand-foot-and-mouth disease caused by coxsackievirus A6 on the rise. Cutis. 2018;102(5):353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">30566537</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu LF, Zheng QB, Li SW, et al. . Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8(1):505. 10.1038/s41467-017-00477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00477-9</ArticleId><ArticleId IdType="pmc">PMC5593947</ArticleId><ArticleId IdType="pubmed">28894095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandary MB, Poh CL.. Changes in the EV-A71 genome through recombination and spontaneous mutations: impact on virulence. Viruses. 2018;10(6):320. 10.3390/v10060320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10060320</ArticleId><ArticleId IdType="pmc">PMC6024729</ArticleId><ArticleId IdType="pubmed">29895721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XH, Li YY, Zhang CB, et al. . Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by coxsackievirus A6. Infect Genet Evol. 2020;77:104054. 10.1016/j.meegid.2019.104054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2019.104054</ArticleId><ArticleId IdType="pubmed">31683008</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Chang SC, Tsao KC, et al. . Comparative genomic analysis of coxsackievirus A6 strains of different clinical disease entities. PLoS One. 2012;7(12):e52432. 10.1371/journal.pone.0052432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052432</ArticleId><ArticleId IdType="pmc">PMC3530459</ArticleId><ArticleId IdType="pubmed">23300669</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, Klemola P, Kaijalainen S, et al. . Co-circulating of coxsackievirus A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol. 2010;48:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaunt E, Harvala H, Osterback R, et al. . Genetic characterization of human coxsackievirus A6 variants associated with atypical hand, foot and mouth disease: a potential role of recombination in emergence and pathogenicity. J Gen Virol. 2015;96(5):1067&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631059</ArticleId><ArticleId IdType="pubmed">25614593</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Xu WB, Xia JL, et al. . Efficacy, safety and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Wu SR, et al. . Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Shen CY, Zhang C, et al. . Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27315772</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Yan B, Yeo HM, et al. . A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol. 2012;86(4):2121&#x2013;2131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma SZ, Zhu LM, et al. . Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model. Antiviral Res. 2017;137:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">27864074</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, et al. . A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78(15):7916&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duo JY, Liu JN, et al. . A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 2011;13(10):862&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao PP, Qian L, Xia Y, et al. . Enterovirus 71-induced neurological disorders in young gerbils, meriones unguiculatus: development and application of a neurological disease model. PLoS One. 2012;7(12):e51996. 10.1371/journal.pone.0051996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0051996</ArticleId><ArticleId IdType="pmc">PMC3528719</ArticleId><ArticleId IdType="pubmed">23284845</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Yu SL, Shao HY, et al. . Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One. 2013;8(2):e57591. 10.1371/journal.pone.0057591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057591</ArticleId><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii K, Nagata N, Sato Y, et al. . Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA. 2013;110(36):14753&#x2013;14758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767555</ArticleId><ArticleId IdType="pubmed">23959904</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang YP, Gao R, et al. . A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol. 2012;86(22):11967&#x2013;11976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen CY, Liu QW, Zhou Y, et al. . Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34(41):5005&#x2013;5012.</Citation><ArticleIdList><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SX, Zhao H, Yang LS, et al. . A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Res. 2017;144:247&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">28625478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Li J, et al. . Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol. 2017;91(13):e00333&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5469256</ArticleId><ArticleId IdType="pubmed">28424287</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen CY, Ku ZQ, Zhou Y, et al. . Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. Vaccine. 2016;34(34):4025&#x2013;4031.</Citation><ArticleIdList><ArticleId IdType="pubmed">27340093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Wei QJ, et al. . A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol. 2017;91(9):e02450&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391469</ArticleId><ArticleId IdType="pubmed">28250116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Dong ZP, Wang Q, et al. . Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095&#x2013;7104.</Citation><ArticleIdList><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LS, Mao QY, Li SX, et al. . A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Res. 2016;134:50&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">27582066</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai WL, Zhang C, et al. . A virus-like particle-based tetravalent vaccine for hand, foot and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):94. 10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Fuchs J, Das SC, et al. . Efficacy of a trivalent hand, foot and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7(11):5919&#x2013;5932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664989</ArticleId><ArticleId IdType="pubmed">26593938</ArticleId></ArticleIdList></Reference><Reference><Citation>Standardization Administration of China . Laboratory animal guideline for ethical review of animal welfare. 2018. Standardization Administration of China, Beijing, China.</Citation></Reference><Reference><Citation>Reed LJ, Muench H.. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493&#x2013;497.</Citation></Reference><Reference><Citation>Khong WX, Foo DGW, Trasti SL, et al. . Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol. 2011;85(7):3067&#x2013;3076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T-Y, Hsia S-H, Huang Y-C, et al. . Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis. 2003;36(3):269&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao P, Wu XX, Li HB, et al. . Clinical significance of inflammatory cytokine and chemokine expression in hand, foot and mouth disease. Mol Med Rep. 2017;15(5):2859&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">28447721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang WJ, Huang ZG, Huang MY, et al. . Predicting severe enterovirus 71-infected hand, foot and mouth disease: cytokines and chemokines. Mediators Inflamm. 2020;2020:9273241. 10.1155/2020/9273241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9273241</ArticleId><ArticleId IdType="pmc">PMC7013319</ArticleId><ArticleId IdType="pubmed">32089650</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan GC, Yang HY, Shi LB, et al. . Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study. PLoS One. 2014;9(11):e112676. 10.1371/journal.pone.0112676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0112676</ArticleId><ArticleId IdType="pmc">PMC4229228</ArticleId><ArticleId IdType="pubmed">25391156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang ZJ, Zhang XC, Carr MJ, et al. . A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg Microbes Infect. 2019;8(1):1445&#x2013;1455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792045</ArticleId><ArticleId IdType="pubmed">31595827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin WP, Lu J, Zhang XY, et al. . Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model. J Virol. 2021;95:e01743&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094937</ArticleId><ArticleId IdType="pubmed">33408178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, et al. . Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000;7(6):523&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KT, Lin SJ, Wang HC, et al. . Establishment of an animal challenge model as a potency assay for an inactivated enterovirus type 71 vaccine. Biologicals. 2016;44(4):183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">27068365</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Sabo D, Taniguchi T, et al. . Nucleotide sequence heterogeneity of an RNA phage population. Cell. 1978;13(4):735&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pubmed">657273</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo E, Holland JJ.. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343347</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine EA, Moncla LH, Ronderos MD, et al. . A single mutation in the VP1 of enterovirus 71 is responsible for increased virulence and neurotropism in adult interferon-deficient mice. J Virol. 2016;90(19):8592&#x2013;8604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5021399</ArticleId><ArticleId IdType="pubmed">27440896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster KZ, Pfeiffer JK.. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response. PLoS Pathog. 2010;6(3):e1000791. 10.1371/journal.ppat.1000791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000791</ArticleId><ArticleId IdType="pmc">PMC2832671</ArticleId><ArticleId IdType="pubmed">20221252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren R, Racaniello VR.. Poliovirus spreads from muscle to the central nervous system by neutral pathways. J Infect Dis. 1992;166(4):747&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">1326581</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>